AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline

AbbVie Inc. ABBV shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11.

Quarterly sales of $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion. Revenues soared 5.6% on a reported basis, or 6.1% on an operational basis.

Global net revenues from the immunology portfolio were $7.294 billion, an increase of 5.3% on an operational basis.

Humira net revenues decreased 48.7% on an operational basis to $1.682 billion, Skyrizi net revenues rose 57.9% to $3.778 billion, and Rinvoq revenues gained 47.1% to $1.834 billion.

“We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity,” said Robert A. Michael, chief executive officer, AbbVie.

Also Read: Chevron Q4 Earnings: Profits Decline Amid Lower Oil Output, Dividend Hike Offers Silver Lining

Global net revenues from the oncology portfolio were $1.691 billion, an increase of 12.9% on an operational basis.

Imbruvica net revenues were $848 million, a decrease of 6.2%, Venclexta net revenues were $655 million, an increase of 13% on an operational basis, and Global Elahere net revenues were $148 million.

Global net revenues from the neuroscience portfolio were $2.509 billion, an increase of 19.8% on a reported basis or 19.9% on an operational basis.

Botox Therapeutic net revenues were $873 million, an increase of 13% on an operational basis, Vraylar net revenues were $924 million, an increase of 17.1%, Ubrelvy net revenues were $303 million, an increase of 29.6%, and Qulipta net revenues were $201 million, an increase of 76.2% on an operational basis.

Outlook: AbbVie sees FY25 adjusted EPS of $12.12 – $12.32 versus the street view of $12.18.

AbbVie is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. 

AbbVie is increasing its 2027 revenue forecast for Skyrizi and Rinvoq to over $31 billion, up $4 billion from the previous guidance. This includes over $20 billion for Skyrizi and over $11 billion for Rinvoq.

AbbVie is also updating its outlook for aesthetics revenues. The company now expects a high single-digit compound annual revenue growth rate for aesthetics through 2029.

Price Action: ABBV shares are trading higher by 7.87% to $189.47 at last check Friday.

Read Next:

Photo: Formatoriginal/Shutterstock.com.